Novocure wins CE Mark for Optune Pax pancreatic cancer use
Novocure (NASDAQ:NVCR) said its Optune Pax device has received CE Mark approval for treating adult patients with locally advanced pancreatic cancer of exocrine origin in combination with gemcitabine and nab-paclitaxel.










